Cosmetic skin-care marketers may be able to breathe easier in 2017, with FDA potentially shifting its focus away from anti-aging claims that identify products as unapproved drugs.
The agency issued upwards of 30 warning letters in 2016 to companies for excessive anti-aging claims related to skin diseases or body structure/function effects, including statements about acne, eczema and psoriasis
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?